Altimmune reports positive results in weight-loss drug trial
In this article:
Multinational biopharmaceutical company Altimmune (ALT) reports positive results in Phase 2 trials for its weight-loss drug, pemvidutide.
Yahoo Finance Health Reporter Anjalee Khemlani explains the results of the trial, including lean mass loss figures recorded from participants.
For more expert insight and the latest market action, click here to watch this full episode of Market Domination.
This post was written by Luke Carberry Mogan.